DORZOLAMIDE OPHTHALMIC SOLUTION
MARKETED BY
: Micro Labs USA Inc
COMPARE TO: Trusopt Patients with glaucoma now have 2 new treatment options with Micro Labs’ dorzolamide HCL ophthalmic solution 2% and dorzolamide HCI and timolol maleate ophthalmic solution 22.3 mg/ 6.8 mg per mL. Dorzolamide, a carbonic anhydrase inhibitor, works to decrease intraocular pressure, a characteristic of glaucoma. According to Micro Labs, the company is doubling its manufacturing capacities to address the growing demand for these 2 ophthalmic solutions.
FOR MORE INFORMATION: microlabsusa.com



SAPROPTERIN DIHYDROCHLORIDE TABLETS, POWDER FOR ORAL SOLUTION
MARKETED BY:
Par Pharmaceutical
COMPARE TO: Kuvan Par Pharmaceutical’s sapropterin dihydrochloride tablets, 100 mg, and powder for oral solution, 100 mg and 500 mg, are the first—and so far, only— generic versions of Kuvan available, and they are indicated to lower blood phenylalanine levels in children older than 1 month and adults with a certain type of phenylketonuria. If left untreated, phenylketonuria can lead to behavioral problems, intellectual disability, mental disorders, and seizures. According to BioMarin Pharmaceutical Inc, Kuvan tablets and powder for oral solution had a market value of approximately $489 million for the 12 months ended June 30, 2020.
FOR MORE INFORMATION: endo.com



DIMETHYL FUMARATE DELAYED-RELEASE CAPSULES
MARKETED BY:
Glenmark Pharmaceuticals Inc, USA
COMPARE TO: Tecfidera The FDA recently approved Glenmark’s generic dimethyl fumarate delayed-release capsules in strengths of 120 mg and 240 mg. The capsules are indicated for adult patients with relapsing forms of multiple sclerosis, including active secondary progressive disease, clinically isolated syndrome, and relapsing-remitting disease. Serious adverse effects include allergic reactions, decreased white blood cell count, herpes zoster infections, and liver problems. The most common and more minor adverse effects include diarrhea, flushing, nausea, redness, and stomach pain.
FOR MORE INFORMATION: glenmarkpharma.com



BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE TABLETS
MARKETED BY:
Strides Pharma Science Limited
COMPARE TO: Fioricet Strides Pharma is offering a new option for patients seeking relief from tension headaches caused by muscle contractions with the recent FDA approval of butalbital, acetaminophen, caffeine tablets USP, 50 mg/325 mg/40 mg. Acetaminophen decreases pain, caffeine boosts the effects of the acetaminophen, and butalbital decreases anxiety and promotes relaxation. According to the company, IQVIA July 2020 data showed that Fioricet had a market value of approximately $40 million.
FOR MORE INFORMATION: strides.com